image

Holistick is developing a device to treat common heart defects, including patent foramen ovale (PFO), a septal defect that causes a blood flow between the two atria and is observed in one out of four individuals. Three clinical studies recently published in the New England Journal of Medicine show that in patients under 60, PFO closure significantly reduces the risk of recurring stroke. These studies led the FDA to approve two devices in this indication. Unlike current metallic implants, Holistick uses flexible materials, allowing for an atraumatic PFO closure that respects the integrity of the cardiac septum.
Holistick owns the exclusive, global licensing rights for this heart-defect repair technology, jointly developed by Harvard and the Massachusetts Institute of Technology (MIT). Holistick was created by Truffle Capital, with the firm’s new BioMedTech fund.

Company’s Keywords:

Q How Many Employees Does This Company Have?

17

Q Which Industry Does This Company Belong To?

medical devices

Q What Is the Annual Income?

Q What Is the Technology of All the Company’s Website?

Outlook, Google Font API, Google Plus, Mobile Friendly

Q What Year Was the Company Founded?

2017

Rate us and Write a Review

Your review is recommended to be at least 140 characters long

image

building Own or work here? Claim Now! Claim Now!

imageYour request has been submitted successfully.

image